HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Post-polycythemia myeloid metaplasia: experience with a large cohort of patients.

Abstract
The common origin of myeloproliferative disorders can explain the possible evolution of polycythemia vera to post-polycythemia myeloid metaplasia (PPMM). Such a possible event is usually considered linked to the use of myelosuppressive agents in particular 32P. Occasionally, myelofibrosis following essential thrombocythemia has also been described. We report here 19 cases of post-polycythemia myeloid metaplasia out of 214 polycythemia vera patients (8.8%). The majority of these patients received 32P therapy. However, busulfan also seems to have some role in the modification of polycythemia vera. In particular, the association of more than one myelosuppressive agent may favour the evolution of PPMM.
AuthorsM L Randi, E Barbone, F Fabris, L Varotto, C Macri, A Girolami
JournalJournal of medicine (J Med) Vol. 25 Issue 6 Pg. 363-9 ( 1994) ISSN: 0025-7850 [Print] UNITED STATES
PMID7769374 (Publication Type: Journal Article)
Topics
  • Adult
  • Aged
  • Cohort Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Polycythemia Vera (complications, therapy)
  • Prevalence
  • Primary Myelofibrosis (epidemiology, etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: